Stanila Stoeva* and Petko Marinov
Background: The risk of toxicity for the healthy individuals who are chronically exposed to cytostatic drugs was established in 1970s. Since then, many institutions have recommended monitoring of the occupational exposure to antineoplastic agents. Nevertheless, there is still a lack of analytical procedures for the whole group representatives. The prodrug Capecitabine is an example of cytostatic that has never been analyzed for the purpose of occupational exposure inspection. Thus, the objective of the present study was to develop a suitable protocol for its evaluation on workplace surfaces.
Methods: Тo determine the surface residue of Capecitabine in laboratory setting а HPLC-UV method, preceded by an appropriate sample preparation procedure, has been carried out. It was used for the pre- and post-cleaning analysis of wipe samples from several working sites, assessed as the most likely ones for the occurrence of dermal contact with the prodrug.
Results: The applied HPLC-UV method was assessed as accurate and precise, with an established limit of quantification of 0.05 µg/mL. The composition of the analytical procedure provided a recovery of Capecitabine more than 90%. During the analytical protocol approbation, one surface sample containing Capecitabine was detected. To determine the efficiency of routine hygiene measures wipe samples from all tested surfaces were analyzed after a cleaning procedure. However, the presence of the cytostatic was not determined, including on the area that gave a positive result.
Conclusion: The analytical protocol developed here successfully permits, for the first time, to study the surface contamination with the cytotoxic agent Capecitabine. Due to this, it can be concluded that the proposed method could be useful for institutions where a potential risk of contamination to the prodrug exists.
Capecitabine, HPLC-UV, occupational exposure, wipe sample
Department of Pharmacology, Toxicology, and Pharmacotherapy, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”, Varna, Department of Pharmacology, Toxicology, and Pharmacotherapy, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”, Varna